Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study. - Wikidata - wikimedia - TriplyDB

Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.

Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.

http://www.wikidata.org/entity/Q33400558

about

A Quinone-Containing Compound Enhances Camptothecin-Induced Apoptosis of Lung Cancer Through Modulating Endogenous ROS and ERK Signaling.

P2860

Q46484915-771FA86C-E4EA-404E-96E1-571FE997EB88

P2860

Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.

http://www.wikidata.org/entity/Q33400558

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Irinotecan plus mitomycin C as ...... platin: a retrospective study.

@ast

Irinotecan plus mitomycin C as ...... platin: a retrospective study.

@en

type

label

Irinotecan plus mitomycin C as ...... platin: a retrospective study.

@ast

Irinotecan plus mitomycin C as ...... platin: a retrospective study.

@en

prefLabel

Irinotecan plus mitomycin C as ...... platin: a retrospective study.

@ast

Irinotecan plus mitomycin C as ...... platin: a retrospective study.

@en

P1433

Q33400558-47CDA9D7-2E77-4EB0-BDB4-E1CBDF1A416C

P1476

Q33400558-D6B13E78-00F0-44C2-86AC-10C3BD4D4C39

P2093

Q33400558-0CC2DC6B-C4B8-4503-B834-F6E266CE3A43

Q33400558-2586207B-FB19-4C55-A061-21D0CD809AA6

Q33400558-2E617334-EEFB-4ADD-845C-8FDC413F4BE4

Q33400558-417047B8-BD87-40C1-8287-939826D7EB53

Q33400558-45010557-9125-4801-B7B8-B82CD1C8E01A

Q33400558-67B81BA5-9D8B-485E-8B15-810304E775A4

Q33400558-6B1BA642-7467-48A7-80D2-2AD55FF1520C

Q33400558-7D1BCF72-33BB-41E4-83AE-8548EB840698

Q33400558-C6FB6249-9B91-47D8-91EC-EE2617FCC7D9

Q33400558-D49E0639-6382-4FBD-93DB-C5CF2A7ACC8D

P2860

Q33400558-0539E3B5-685F-49DD-979B-3FFA1C9918E3

Q33400558-10278FFA-7B6D-4AC8-ABDB-EE55856CA839

Q33400558-1AE4D1E5-C7E2-42D1-BA71-93CCF650919E

Q33400558-2F5F78E6-6332-48DB-ACE9-1860E30EE375

Q33400558-2F646C6B-130E-4B56-9140-E6A185A284B5

Q33400558-3525E804-EA96-40A2-A913-AE668DE91D84

Q33400558-36A8E461-7A02-4FF6-A740-437D0F078C4D

Q33400558-503DB05D-ED21-4FD5-8F62-F44E8B2E8D07

Q33400558-7D98C3BA-2ABA-4AC2-B7BD-6ECA84130A8A

Q33400558-91C0BC3D-8450-4235-9A4C-B62876D1131D

P304

Q33400558-CA665844-9044-4AB7-B0A5-D1F44BFB7943

P31

Q33400558-2ECD5930-220C-42E8-A3AE-6E1EC3A55753

P356

Q33400558-9210A2A9-1457-4567-A3DA-109F5ECB24E4

P478

Q33400558-C10DBD6D-A93D-4659-A85F-9CCE392E8DC4

P50

Q33400558-1ED803E4-36D9-4417-BA6A-6D49FAF31624

P577

Q33400558-97FA9B89-D59C-49CF-9634-45FF6E0D9DBA

P5875

Q33400558-7F9AD6B1-43C1-47F4-8BDC-08AF37CC7BA3

P698

Q33400558-543334BC-BD81-4FE9-A6DA-AA4E9AF67D98

P932

Q33400558-1455179E-52C9-4405-B585-CF85BDE0D3B4

P356

P1433

Gastroenterology research and practice

P1476

Irinotecan plus mitomycin C as ...... platin: a retrospective study.

@en

P2093

Akira Ueda

http://www.w3.org/2001/XMLSchema#string

Ayumu Hosokawa

http://www.w3.org/2001/XMLSchema#string

Hiroshi Mihara

http://www.w3.org/2001/XMLSchema#string

Kohei Ogawa

http://www.w3.org/2001/XMLSchema#string

Kunihiro Sawasaki

http://www.w3.org/2001/XMLSchema#string

Masayuki Note

http://www.w3.org/2001/XMLSchema#string

Mitsuhiro Terada

http://www.w3.org/2001/XMLSchema#string

Naoki Horikawa

http://www.w3.org/2001/XMLSchema#string

Seiko Saito

http://www.w3.org/2001/XMLSchema#string

Shinya Kajiura

http://www.w3.org/2001/XMLSchema#string

P2860

Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).

Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.

A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.

P304

640401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/640401

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223986901

http://www.w3.org/2001/XMLSchema#string

P698

22474446

http://www.w3.org/2001/XMLSchema#string

P932

3296209

http://www.w3.org/2001/XMLSchema#string